Chronic and intermittent administration of systemic nitroglycerin in the rat induces an increase in the gene expression of CGRP in central areas: potential contribution to pain processing

Rosaria Greco, Chiara Demartini, Anna Maria Zanaboni and Cristina Tassorelli

Abstract

Background: Calcitonin gene related peptide (CGRP) is a key neuropeptide involved in the activation of the trigeminovascular system and it is likely related to migraine chronification. Here, we investigated the role of CGRP in an animal model that mimics the chronic migraine condition via repeated and intermittent nitroglycerin (NTG) administration. We also evaluated the modulatory effect of topiramate on this experimental paradigm. Male Sprague-Dawley rats were injected with NTG (5 mg/kg, i.p.) or vehicle, every 2 days over a 9-day period (5 total injections). A group of animals was injected with topiramate (30 mg/kg, i.p.) or saline every day for 9 days. Twenty-four hours after the last administration of NTG or vehicle, animals underwent tail flick test and orofacial Von Frey test. Rats were subsequently sacrificed to evaluate c-Fos and CGRP gene expression in medulla-pons region, cervical spinal cord and trigeminal ganglia.

Results: NTG administration induced spinal hyperalgesia and orofacial allodynia, together with a significant increase in the expression of CGRP and c-Fos genes in trigeminal ganglia and central areas. Topiramate treatment prevented NTG-induced changes by reversing NTG-induced hyperalgesia and allodynia, and inhibiting CGRP and c-Fos gene expression in all areas evaluated.

Conclusions: These findings point to the role of CGRP in the processes underlying migraine chronification and suggest a possible interaction with gamma-aminobutyrate (GABA) and glutamate transmission to induce/maintain central sensitization and to contribute to the dysregulation of descending pain system involved in chronic migraine.

Keywords: Nitroglycerin, Topiramate, CGRP, Trigeminal nociception

Background

Pain persistence is associated with peripheral and central nervous system reorganization involving neuronal and glial changes [1]. Migraine chronification may result from maladaptive neuroplasticity along the nociceptive pathway [2]. Repeated trigeminal activation at the meningeal neurovascular endings indeed, with the associated neurogenic inflammation, may induce peripheral and central sensitization, which in turn predisposes patients to develop more migraine attacks in a vicious cycle that, in some migraineurs, leads to chronic migraine [3]. The mechanisms involved in migraine chronification are largely elusive; however, a major role seems to be played by the neuropeptide calcitonin gene-related peptide (CGRP), a vasodilatory peptide released by trigeminovascular endings to cause vasodilation, neurogenic inflammation and peripheral sensitization [4]. The role of CGRP in migraine attacks is reinforced by the efficacy of CGRP antagonism in animal models of migraine pain [5–7] and by promising reports on the efficacy of CGRP-related drugs.
in clinical trials, e.g. telcagepant or LY2951742 [8–10]. Recently, monoclonal antibodies directed against CGRP have proved effective in the preventive treatment of chronic migraine [11]. The precise mechanisms and sites where CGRP may act to favor chronification of migraine are still to be identified. CGRP receptors are largely distributed also in the brain, providing a wide range of possible CGRP targets and sites of interactions with other systems [12]. Topiramate is an antiepileptic drug with established efficacy in chronic migraine prevention [13, 14]. The drug likely acts on the cell excitatory mechanisms via its influence on the receptor/channel protein complexes [15–17].

Nitroglycerin (NTG) is a nitric oxide (NO) donor that has been used for years as a provocative test in migraine for diagnostic and research purposes [18, 19]. In rodents, NTG induces an increased sensitivity to pain stimuli [20–22] and its chronic and intermittent administration causes acute plantar mechanical hyperalgesia with a progressive and sustained hyperalgesia [23, 24]. This behavior nicely reflects the increased sensitivity to painful stimuli in migraineurs [25] and therefore may be relevant for understanding the mechanism underlying migraine. Here, we aimed at gathering more insights into the role and mechanisms of CGRP in migraine chronification by chronic migraine-like rat model that mimics the condition of chronic migraine. In this model we evaluated: a) CGRP and c-Fos gene expression in areas involved in trigeminal nociception; b) the nociceptive threshold at the tail flick; c) orofacial mechanical allodynia; d) the modulatory effect of the migraine preventive drug topiramate.

Methods

Animals

We used adult male Sprague-Dawley rats (weight 200–250 g, Charles River, s.r.l, Calco, Lecco, Italy) at the Centralized Animal Facility of the University of Pavia. The animals were housed under standard laboratory conditions in plastic boxes in groups of 2 with water and food available ad libitum and kept on a 12:12 h light-dark cycle, at room temperature of 19–21 °C with relative humidity of 70–80%. All procedures were conducted in accordance with the European Convention for Care and Use of Laboratory Animals and with the IASP’s guidelines for pain research in animals [26]. The experimental protocols were approved by the Italian Ministry of Health (Document number 1239/2015PR).

Drugs

Nitroglycerin (NTG) (Bioindustria L.I.M. Novi Ligure (AL), Italy) was prepared from a stock solution of 5.0 mg/1.5 mL dissolved in 27% alcohol and 73% propylene glycol. For the injections, NTG was further diluted in saline (0.9% NaCl) to reach the final concentration of alcohol 6% and propylene glycol 16%. The diluted NTG is injected intraperitoneally (i.p.) at the dose of 5 mg/Kg [24, 27]. An equivalent volume of saline (0.9% NaCl), alcohol 6% and propylene glycol 16%) was used as vehicle. Topiramate (Topamax, Janssen-Cilag Cologno Monzese (MI), Italy) was dissolved in saline and administered i.p. at the dose of 30 mg/Kg [28]. Before baseline testing, rats were assigned to treatment groups according to a randomization list to ensure blinding to treatments of the researchers who performed the behavioral testing (tail flick test and Von Frey test, see below). Before testing the animals, the blinded examiners were instructed to observe the animal behavior, in order to evaluate the possible impact of topiramate on sedation or locomotor activities.

Experimental design and experimental groups

An a priori power analysis was conducted to determine the minimal sample size needed to obtain a statistical power of 0.80 at an alpha level of 0.05. On the basis of our previous studies in rats evaluating the latency to the tail flick (sec.) before and after NTG, we calculated an effect size of 1.6 for this variable (GPower 3.1.9.2), estimating a sample size of at least 5 rats for experimental group. Rats were injected with NTG or vehicle, every 2 days over a 9-day total period (5 total injections). A group of animals was also injected with topiramate (TOP) or vehicle (saline) every day for 9 days. At baseline (day 0) and 24 h after the last administration of NTG (day 10), the animals belonging to the different experimental groups (see below) underwent the evaluation of the nociceptive threshold by means of the tail flick test and of the orofacial mechanical allodynia by means of the Von Frey test. The schedule of drug treatments is reported in Fig. 1.

Experimental Groups: CT = NTG vehicle + TOP vehicle (N = 10–13 per group); NTG = NTG + TOP vehicle (N = 9–12 per group); TOP = NTG vehicle + Topiramate (N = 5–8 per group); NTG + TOP = NTG + Topiramate (N = 5–8 per group).

Behavioral tests

Rats underwent tail flick test and Von Frey test 30 min apart from each other at baseline and on day 10.

Tail flick test

To determine thermal sensitivity, rats were gently restrained while an infrared light beam with a temperature of 50 °C was focused on the animal’s tail. The latency of retraction of the tail from the window of the light beam was automatically captured and measured (in seconds) by means of a sensor (Ugo Basile, model 7360, Varese, Italy) [20, 21]. A cut-off limit of exposure of 20 s was set to avoid tissue damage. The final latency value for each animal was
calculated as the mean of four measurements in 4 different parts of the tail, specifically at 1, 3, 5 and 7 cm from the tip.

**Von Frey test**
For three consecutive days, prior to baseline testing, the rats were habituated to the behavioral test procedure. Rats were put in clear acrylic cages (30 × 30 × 20 cm) and the orofacial area of the animal was stimulated with a series of Von Frey filaments (bending force ranging from 0.02 to 6 g). Progressively increasing filament forces were applied (each of them 5 times every 30 s) to the cutaneous area on both the left and right sides of the face, over the rostral portion of the eye for periorbital testing and on the skin over the masseter muscle for jaw testing until we obtained a positive response, defined as one of the following: head withdrawal, face wipe, escape/attack. In the absence of a positive response to the starting filament (0.4 g), a heavier filament was applied whereas, with a positive response a lighter filament was tested. The mechanical threshold corresponded to the force of the filament that induced three positive responses [29, 30].

**CGRP and c-Fos gene expression**
On day 10, immediately after undergoing the Von Frey test, all rats were sacrificed and their medulla-pons region, cervical spinal cord (C1-C2) and trigeminal ganglia were immediately chopped into parts for the evaluation of CGRP and c-Fos gene expression. mRNA levels were analyzed by real-time polymerase chain reaction (RT-PCR) as previously described [22, 31]. Primer sequences of Calca gene, coding for CGRP, (forward primer: CAGTCTCAGCTCAAAGTCATC; reverse primer: TTCCAAGGTTTGACCTCAAAG) and c-Fos (forward primer: TACGCTCAAAGCGGAGAC; reverse primer: TTTCCTTCTCTTCTCAAGATTG) were obtained from the AutoPrime software (http://www.autoprime.de/AutoPrimeWeb). We used glyceraldehyde 3-phosphate dehydrogenase (GAPDH; forward primer: AACCTGCCAGTATGATGAC; reverse primer: GGAGTTGCTGTTGAGTCA) as housekeeping gene. All samples were assayed in triplicate. Gene expression was calculated using the ΔΔCt method.

**Data analysis and statistical evaluation**
Our data showed a normal distribution when analyzed with the Kolmogorov–Smirnov (KS) normality tests. For the behavioral tests the inter-groups and within groups differences between baseline and post-treatment timings were analyzed using the Two-way ANOVA for repeated measures followed by Bonferroni post hoc test. For gene expression, the differences between groups were analyzed by One-way ANOVA followed by Newman–Keuls multiple comparison test. A p value < 0.05 was considered statistically significant. The results were reported in the figures and all data were expressed as the mean ± standard error of the mean. The Statistical analysis was performed using GraphPad Prism 5.02.

**Results**

**Behavioral testing**
No distinctive pattern of behavior was identified in the different experimental groups by comparing the reports of the blinded observers after treatment unblinding.

**Tail Flick test**
No significant difference among CT, NTG and NTG + TOP groups was observed at baseline (Fig. 2a). Chronic NTG administration caused a state of hyperalgesia, which was detected as a reduction in the latency at the tail flick test performed on day 10 as compared with both baseline value and CT group. The chronic administration of topiramate did not influence the tail flick latency, but it prevented NTG-induced hyperalgesic state. Data are reported in Fig. 2a.

**Von Frey test**
We did not detect any significant difference in baseline mechanical sensitivity among experimental groups (Fig. 2b). Chronic and intermittent NTG administration caused orofacial allodynia with a reduction in the mechanical pain threshold compared to the baseline value and to
the CT group. Topiramate did not change the mechanical pain threshold when compared to the baseline value and to the CT group, but it prevented the development of NTG-induced allodynia. The mechanical threshold of NTG + TOP was increased compared to NTG group, although it did not reach a statistical significant level, probably because of the great variability of data. Data are reported in Fig. 2b.

mRNA expression of CGRP and c-Fos genes

NTG administration induced a significant increase in the expression of c-Fos and CGRP mRNA in the medulla-pons region, cervical spinal cord and trigeminal ganglia (Fig. 3). Topiramate did not modify genes expression in these areas when used alone, but it markedly attenuated CGRP and c-Fos gene expression induced by NTG in all the areas under evaluation (Fig. 3).
Discussion

Migraine is a highly disabling condition [32] that manifests with recurring attacks. In 2–3% of the general population it becomes chronic (≥ 15 days/months) and therefore even more disabling. Progressive changes in nociceptive thresholds and subsequent central sensitization due to recurrent migraine headaches in vulnerable subjects contribute to the chronic migraine state. Understanding the mechanisms of chronification seems therefore extremely useful. The role of CGRP in the precipitation of migraine attacks is nowadays well accepted [33]. Less known is CGRP role in the processes that lead to migraine chronification.

Several studies indicate that NTG administration in rodents is a predictive model of migraine in humans [24, 34, 35]. In this study we aimed at developing and testing a chronic migraine-like model in rats, based on chronic and intermittent administration of NTG. In this model the animals become hyperalgesic and allodynic, which nicely mimics the clinical picture on one side [25, 36–39], and, on the other, parallels the findings obtained by Pradhan et al. in the animal model of chronic migraine devised in mice [24]. The availability of an animal model of chronic migraine in rats provides a precious opportunity for investigating the pathophysiological mechanisms involved in chronic migraine for a dual reason: 1) rat models have technical and practical advantages [40] and 2) the rat-based migraine model of acute NTG administration is well-established and has already yielded a wealth of data from several groups [41, 42].

Using this chronic migraine-like model we showed that the observed changes in pain perception – namely a reduction in the latency of the tail flick test and orofacial mechanical allodynia - are paralleled by an increased expression in CGRP mRNA in the trigeminal ganglia. CGRP is involved in the maintenance of ongoing sensitization and the increased gene expression observed in our model may be interpreted as a compensatory mechanism for reintegrating CGRP released at the trigeminovascular endings [43–45]. In agreement, Farajdokht et al. [46] demonstrated that the increase in CGRP gene expression in trigeminal ganglia is associated with increased transient receptor potential vanilloid type-1 mRNA levels in the same area 48 h after NTG injection. Previous reports have suggested that NTG induces hyperalgesia via complex mechanisms that involve also sensitization of the trigeminovascular system at the meningeal level [47–49]. Previ...
preclinical studies showing that topiramate has an anti-allodynic effect in neuropathic pain at doses of 20–50 mg/kg [28, 63–65]. Chronic administration of topiramate (50 mg/kg/day, i.p.) to neuropathic rats diminished the mechanical sensitivity and shortened the period of allodynia to 8 days [28].

CGRP can directly activate the nociceptors or facilitate their firing, thus causing peripheral sensitization and hyperalgesia [1]. In this frame, it is possible that the anti-hyperalgesic effect of topiramate observed in the present study is related to the inhibitory activity on the neuronal firing within the trigeminocervical complex and the ventroposteromedial thalamic nucleus, as reported by Andreou and Goadsby [66].

Topiramate blocks voltage-dependent sodium channel in spinal cord neurons, which prompts a possible mechanism for reducing afferent input to the NTC [67]. Other mechanisms could be involved such as anti-inflammatory and immunomodulatory effects or inhibition of neurotransmitters release [68, 69]. Central sensitization involves an increased sensitivity of second-order neurons to afferent inputs, the augmentation of receptive fields and an increased excitability; furthermore, it involves long-term effects related to transcriptional changes and dysfunctions in the descending pain system [70]. The maintenance of central sensitization may be related to the activation of the glutamate N-methyl-D-aspartate (NMDA), AMPA and metabotropic receptors. Thus, AMPA/kainate receptors inhibition by topiramate treatment could decrease neuronal hyperexcitability within the NTC and brain structures receiving inputs from second order neurons [68]. Glutamate-like immunoreactivity has been indeed detected in tooth pulp neurons that project to the NTC in the rat [71].

It is worth noting that in our experimental paradigm, topiramate treatment significantly reduced CGRP gene expression in cervical spinal cord and medulla-pons. In agreement, topiramate treatment repressed KCl stimulated CGRP release in a time and concentration dependent manner in trigeminal cultures [72]. However, since GABAergic mechanisms have been shown to be implicated in the trigeminocervical complex, it is stimulating to hypothesize that GABA potentiation due to topiramate treatment may interfere with CGRP synthesis in the NTC, as well as in the areas involved in the descending pain system [34, 35, 57, 73]. Synaptic contacts between CGRP-positive terminals and GABAergic neurons were found within the CeA, which may underlie the pain-related neural pathway from PBN to CeA, in chronic pain modulation.

The increased c-Fos mRNA levels found 24 h after NTG treatment, confirms that NTG-induced transcriptional changes are not limited to peripheral areas, but rather affect central structures, directly or indirectly, thus reflecting a widespread, peripheral and central diffusion of sensitization phenomena consistent with the observed alterations in pain responses. While a large body of information has been collected over the years by our group and others on the acute NTG model, the mechanisms responsible for c-Fos gene expression after chronic NTG are almost completely unknown. At this time, we can only speculate that the model proposed in this study actually engages the CNS with persisting functional and morphological changes associated to chronic sensitization.

Limitations of the study
The design of study foresaw the chronic administration of topiramate. Data from the literature suggest that acute administration of topiramate reduces neuronal firing in the trigeminovascular complex [66] therefore the chronic administration used in our design might not have been necessary. In the absence of reliable evidence, we selected the chronic administration for several reasons. First, this treatment schedule reflects more closely the clinical scenario, where topiramate is used daily over months to prevent migraine attacks. Second, data is lacking on the serum/plasma concentration of topiramate observed in the present study. This could have been addressed by increasing the dose of the single administration, but also the possibility that the sedative effect of such a higher dose might interfere with the nocifensive behavior of the rat [77]. The lack of precise pharmacokinetics studies on repeated dosing in the laboratory animal ultimately suggested the selection of dose regimens based on a best-guess modality, guided by careful evaluation of available evidence.

Future studies are needed to address topiramate serum/plasma concentrations in our model, together with the evaluation of the potential impact of topiramate-induced locomotor activity in the nocifensive behavior of chronically NTG-treated rats using specific behavioral testing.

Conclusions
The present findings, obtained in a novel chronic migraine-like model in the rat, suggest that CGRP pathway activation is involved in the facilitation of nociceptive transmission and is likely to contribute to central sensitization and dysfunction in descending pain control, via modulatory effects that encompass the modulation of voltage dependent sodium channels, GABA activity and the glutamate pathway. A fuller understanding of CGRP effects and CGRP network in brain regions will provide powerful insights for understanding the complex circuitry of migraine and for the improvement of migraine therapies.

Abbreviations
AMPA: α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; CeA: Central nucleus of the amygdala; CGRP: Calcitonin gene-related peptide;
GABA: Gamma-aminobutyrate; GAPDH: Glyceraldehyde 3-phosphate dehydrogenase; NMDA: N-methyl-D-aspartate; NO: Nitric oxide; NTG: Nitroglycerin; PBN: Pontine parabrachial nucleus; RTPCR: Real-time polymerase chain reaction; TOP: Topiramate

Funding
This work was supported by a grant of the Italian Ministry of Health (Ricerca Corrente 2016) to the IRCCS Mondino Foundation.

Authors’ contributions
RG designed the experiments and drafted the manuscript. CD and AZ performed the experiments. RG analyzed and interpreted the data. CT revised the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate
All procedures were in accordance with the European Convention for Care and Use of Laboratory Animals and were approved by the Italian Ministry of Health (Document number 1239/2015PR).

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Laboratory of Neurophysiology of Integrative Autonomic Systems, Headache Science Centre, IRCCS Mondino Foundation, Pavia, Italy.
2Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.

Received: 13 March 2018 Accepted: 2 July 2018
Published online: 13 July 2018

References
1. Babauta DM, Scherrer G, Raju D (2009) Cellular and molecular mechanisms of pain. Cell 139(2):267–284
2. Latremoliere A, Woolf CJ (2009) Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J Pain 10(9):895–926
3. Bernstein C, Burstein R (2012) Sensitization of the trigeminovascular nociceptive system by central neural plasticity. J Clin Neuroe 8(2):89–93
4. Iyengar S, Ossipov MH, Johnson KW (2017) The role of calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Neurology 13(9):885–892
5. Greco R, Mangione AS, Siani F, Blandini F, Vairetti M, Nappi G, Sandrini G. (2016) Topiramate blockade on NTG-induced hyperalgesia: evaluation of URB937 in an animal model of migraine. Cephalalgia 35(12):1065–1076
6. Greco R, Sani F, Demartini C, Zanaboni A, Nappi G, Davinelli S, Scapagnini G, Tassorelli C (2016) Anti-diarrheal Pancreatitis shows anti-nociceptive effects in an animal model of sensory hypersensitivity associated with migraine. Funct Neurol 31(3):50–53
7. Aradjojkhut F, Babri S, Karimi P, Alipour MR, Bughchechi R, Mohasses G (2017) Chronic ghrelin treatment reduced photophobia and anxiety-like behaviors in nitroglycerin-induced migraine: role of pituitary adenylate cyclase-activating polypeptide. J Neurosci 45(6):763–772
8. Padhan AA, Smith ML, McGuire B, Tarash I, Evans CJ, Charles A (2014) Characterization of a novel model of chronic migraine. Pain 155(2):269–274
9. Perrotta A, Serra M, Tassorelli C, Arcos-Leal I, Gascó E, Sances G, Rossi P, Bartolo M, Pierelli F, Sandrini G, Nappi G (2011) Oral nitric-oxide donor glyceryl-trinitrate induces sensitization in spinal cord pain processing in migraineurs: a double-blind, placebo-controlled, cross-over study. Eur J Pain 15(5):482–490
10. Zverina J, Zverina J, Zverina J, Zverina J (199) Ethical guidelines for investigations of experimental pain in conscious animals. Pain 161(10–11)
11. Tassorelli C, Greco R, Cappelli R, Sandrini G, Nappi G (2005) Comparative analysis of the neuronal activation and cardiovascular effects of nitroglycerin, sodium nitroprusside and L-arginine. Brain Res 1051(1):17–21
12. Wieczorkiewicz-Plaza A, Plaza P, Maciejewski R, Czuczwar M, Ptaszycki K (2004) Effect of topiramate on mechanical allodynia in neuropathic pain model in rats. Pol J Pharmacol 56(2):275–278
13. Martin YB, Avendaño C (2009) Effects of removal of dietary polysaturated fatty acids on plasma extravasation and mechanical allodynia in a trigeminal neuropathic pain model. Mol Pain 5:8
14. Ochinsky ML, Sanghi M, Bernier R, Gonzalez D, Spangenberg RJ, Cooper M, Silverstein SD (2012) Spontaneous trigeminal allodynia in rats: a model of primary headache. Headache 52(9):136–149
15. Demartini C, Tassorelli C, Zanaboni AM, Tonsi G, Franceschini O, Nativi C, Greco R (2017) The role of the transient receptor potential ankyrin type-1 (TRPA1) channel in migraine pain: evaluation in an animal model. J Headache Pain 18(1):94
16. GBD 2015 Neurological Disorders Collaborator Group (2017) Global, regional, and national burden of neurological disorders during 1990–2015: a}
systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol 16(1):87–89
33. Bjal ME, Walter S, Rapoport AM (2013) Calcitonin gene-related peptide (CGRP) and migraine current understanding and state of development. Headache 53(8):1230–1244
34. Moys E, Pradhan AAI (2017) Animal model of chronic migraine-associated pain. Curr Protoc Neurosci 80:601–960.9
35. Farkas S, Bölcskei K, Markovic S, Varga A, Kisz-Varga A, Kornos V, Gaszner B, Horváth C, Tuka B, Tașst J, Helyes Z (2016) Utility of different outcome measures for the nitroglycerin model of migraine in mice. J Pharmaco Toxicol Methods 77:33–44
36. de Tommaso M, Ambrosini A, Brighina F, Coppola G, Perrotta A, Pierotti A, Pierelli F, Sandrini G, Valeriani M, Marinazzo D, Stramaglia S, Schoenen J (2014) Altered processing of sensory stimuli in patients with migraine. Nat Rev Neurol 10(3):144–155
37. Sandrini G, Tassorelli C, Cecchini AP, Alfonsi E, Nappi G (2002) Effects of nimesulide on nitric oxide-induced hyperalgesia in humans—a neurophysiological study. Eur J Pharmaco 450(3):259–262
38. Burstein R, Jakubowski M, Rauch SD (2011) The science of migraine. J Vestib Res 21(6):305–314
39. Louter MA, Bosker JE, van Oosterhout WP, van Zwet EW, Zitman FG, Ferrari MD, Terwindt GM (2013) Cutaneous allodynia as a predictor of migraine chronification. Brain 136( Pt 11):3489–3496
40. Ellenbroek B, Youn J (2016) Rodent models in neuroscience research: is it a different outcome measures for the nitroglycerin model of migraine?
41. Greco R, Tassorelli C, Sandrini G, Tassorelli C, Valeriani M, Marinazzo D, Stramaglia S, Schoenen J (2002) Effects of systemic nitroglycerin on CGRP and 5-HT afferents to rat caudal trigeminal nucleus and its modulation by estrogen. Eur J Neurosci 15(11):1803–1809
42. Capuano A, Greco MC, Navarra P, Tringali G (2014) Correlation between algogenic effects of calcitonin-gene-related peptide (CGRP) and activation of trigeminal vascular system, in an in vivo experimental model of nitroglycerin-induced sensitization. Eur J Pharmacol 740:97–102
43. Faradokht F, Mohaddes G, Shanehbandi D, Karimi P, Babri S (2017) Ghrelin distribution of CGRP and its receptor components in the trigeminovascular system and other pain related structures in rat brain, and effect of intracerebroventricular administration of CGRP on Fos expression in the TNC. Neurosci Lett 559:99–104
44. Kresse A, Jacobowitz DM, Skofitsch G (1995) Detailed mapping of CGRP mRNA expression in the rat central nervous system: comparison with previous immunocytochemical findings. Brain Res Bull 36(3):261–274
45. Bernard JF, Alden M, Benson JV, BM (1995) The organization of the effector projections from the pontine parabrachial area to the amygdaloid complex: a Phoxodus vulgatus leucoagglutinin (PHA-L) study in the rat. J Comp Neurol 352(2):201–229
46. Eftekhari S, Edvinsson L (2011) Calcitonin gene-related peptide (CGRP) and its receptor components in human and rat trigeminal nucleus and spinal cord at C1-level. BMC Neurosci 12:112
47. Eftekhari S, Gaspar RC, Roberts R, Chen TB, Zeng Z, Villarreal S, Edvinsson L, Salvatore CA (2016) Localization of CGRP receptor components and receptor binding sites in threes monkey brainstem: a detailed study used in situ hybridization, immunofluorescence, and autoradiography. J Comp Neurol 524:90–118
48. Silberstein S, Lipton R, Dodick D, Feitig F, Mathew N, Brandes J, Bigal M, Ascher S, Morein J, Wright P, Greenberg S, Sullivan J (2009) Topiramate treatment of chronic migraine: a randomized, placebo-controlled trial of quality of life and other efficacy measures. Headache 49(1153–1162
49. Ownen HC, Buscone G, Van Oene J, Lahaye M, Schwalen S, Goasdby PJ, TOPMAT-MIG-201(TOP-CROME) Study Group (2007) Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia 27:814–823
50. Ambrosini A, Schoenen J (2006) Electrophysiological response patterns of primary sensory cortices in migraine. J Headache Pain 7:377–388
51. Shank RP, Gardocki JF, Streeter AJ, Manayoff BE (2000) An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics and mechanism of action. Epilepsia 41(Suppl 1):53–59
52. Angehagen M, Ben-Menachem E, Rönndbäck L, Hansson E (2003) Novel mechanisms of action of three antiepileptic drugs, vigabatrin, gabapentin, and topiramate. Neurochem Res 28(2):333–340
53. Benoliel R, Tal M, Elav E (2006) Effects of topiramate on the chronic-constriction injury model in the rat. J Pain 7:878–883
54. Rus NN, Bocjan C, Vesa Š, Coadă CA, Buzoianu AD (2013) Topiramate in nociceptive pain - experimental analgesia study. Human & Vet Med Int J Bioflux Soc 770–776
55. Wild KD, Yagle SK, Shank RP (1997) The novel anticonvulsant-sodium topiramate is antialloynic in a rat model of neuropathic pain. Soc Neurosci Abstr 23:2358 abstr 918.10
56. Andreou AP, Goadsby PJ (2011) Topiramate in the treatment of migraine: a kainate (glutamate) receptor antagonist within the trigeminothalamic pathway. Cephalalgia 31(13):1343–1358
57. McLean MJ, Bukhari AA, Wamil AW (2000) Effects of topiramate on sodium-dependent action-potential firing by mouse spinal cord neurons in cell culture. Epilepsia 41(Suppl 1):521–524
58. Schiffer WK, Gerasimov MR, Marsteller DA, Geiger J, Barnett C, Alexoff DL, Mayer A, Manayoff BE (2000) Molecular pharmacodynamics, clinical therapeutics, and pharmacokinetics of topiramate. CNS Neurosci Ther 14(2):120–142
59. Benarroch EE (2011) CGRP: sensory neuropeptide with multiple neurologic implications. Neurology 77(3):281–287
60. Bouhassira D, Le Bars D, Villeneuve L (1987) Heterotopic activation of ad and C fibres triggers inhibition of trigeminal and spinal convergent neurons in the rat. J Physiol 389:301–317
61. Durham PL, Niemann C, Cady R (2006) Reexpression of stimulated calcitonin gene-related peptide secretion by topiramate. Headache 46(8):1291–1295
62. Lauer BK, Vaughan CW (2014) Descending modulation of pain: the GABA disinhibition hypothesis of analgesia. Curr Opin Neurobiol 29:159–164
63. Johannessen SI (1997) Pharmacokinetics and interaction profile of topiramate: review and comparison with other newer antiepileptic drugs. Epilepsy 38(Suppl 1):S18–S23
64. Matar KM, Tayem YI (2014) Effect of experimentally induced hepatic stress and inflammation in rat isolated hippocampus. Clin Exp Pharmacol Physiol 43(3):360–371